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Summary: Neopterin excretion in urine and the serum concentrations of neopterin were compared in 101
patients with a malignant melanoma of the choroid and in a matched group of healthy volunteers. The
majority of cases (n = 99) presented an untreated (n = 20) or treated and either partially (n = 33) or
completely regressed (n = 47) melanoma of stage I —III without signs of extraocular manifestation at the
time of analyses. The incidence of elevated neopterin concentrations in all melanoma patients beyond the
upper limit (x + 2 S.D. of healthy controls) was 16% for both serum and urine. In patients with critical
events, for example orbital infiltration or delayed metastatic disease during the subsequent follow-up period
(at least 14 months), the neopterin concentrations were at the higher end of distribution. One patient with
verified metastatic disease at the time of analysis presented extremely elevated neopterin concentrations in
serum (82.3 nmol/1) and urine (1608 μιηοΐ/mol creatinine). It seems that the results of neopterin analyses are
informative as a prognostic factor for the follow-up of patients with a malignant melanoma of the choroid.
Introduction
In recent years neopterin has been established as a
clinically useful indicator of cellular immunity and,
therefore, of tumour-associated cellular reactions
(1 —4). Neopterin-positive cases are regularly associ-
ated with haematological neoplasias, whereas in most
kinds of solid tumours the association of a neopterin
increase tends to be less frequent. In certain types of
solid tumours neopterin correlates with staging (2, 5)
and seems to be useful as a prognostic factor for the
monitoring of affected patients, whereas in most other
situations neopterin concentrations are independent
of the tumour stage. Patients with malignant mela-
noma of the choroid have so far not been the focus
of neopterin analyses, but there is one report of ele-
vated neopterin levels in cases of cutaneous malignant
melanomas with visceral metastases (5). Since both
kinds of tumour share some immunological properties
(6), and the longterm prognosis of choroidal mela-
* Submitted February 7/August 31,1992 to "Pteridines" which
discontinued with vol. 3, no. 3, 1992
noma is much better than that of cutaneous mela-
noma, it seemed worthwhile to look for a relation
between neopterin and tumour stage, as well as pos-
sible correlation with the occurence of metastases.
Material and Methods
One hundred and one patients with a malignant melanoma of
the choroid were enroled in this study on neopterin excretion.
According to the clinical situation patients were classified as:
(a) untreated,
(b) incomplete tumour regression after brachytherapy with
I06Ru/106Rh-applicators,
(c) presumed complete tumour regression after brachytherapy.
In addition, neopterin was determined in the sera of 43 of these
patients. At the time of pterin analysis one patient presented
metastases of the tumour (hepatic, pulmonary, osseous; stage
IVb). In two further patients metastases were diagnosed during
the period of clinical follow up (at least 14 months), 7 and 10
months after analysis, respectively. One patient presented a
transscleral infiltration of the orbita (stage IVa). Neopterin
results from tumour patients were compared with those from
healthy volunteers. Healthy controls for this study were selected
so that they matched the patients as closely as possible with
respect to sex and age. For basic statistical information on the
age and sex-ratio of examined groups see table 1.
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Tab. 1. Statistical characterisation of the examined groups of
patients with choroidal melanoma and healthy controls
(F = female, M = male, n = number of patients).
Urine Serum
Melanoma Control Melanoma Control
(n)
Age χ ± S. D.
(years)
Age (range)
(years)
101
61.3
±11.9
48
-88
92
59.2
±12.5
47
-84
43
60.5
±10.8
48
-88
40
59.8
±11.4
47
-83
Sex $ : 54 : 47 48 : 44 23 : 20 21 : 19
Samples were collected from all patients and healthy volunteers
between 9 and 12 o'clock in the morning, in order to avoid any
bias by circadian variations (7).
Neopterin analysis of urine and serum was performed under
oxidative conditions by fluorometric HPLC-detection. Urine
was analysed according to Goldberg's (8) modification of the
Fukushima & Nixon (9) procedure. Immediately after collection,
1 ml of each specimen was incubated with 300 μΐ of 1 mol/1
HC1 and 200 μΐ of 5 g/112/10 g/1 KI in 0.1 mol/1 HC1 in darkness.
After 1 h, excess iodine was reduced with 200 μΐ of ascorbic
acid. Further purification was performed with Dowex H+
(Dowex 50 WX8, 100-200 mesh) as previously reported (8).
Serum samples (3 ml) were incubated with 2 ml of 2 mol/1
trichloroacetic acid. Iodine was added to this incubation in the
same proportion as in the oxidative step of the urine analyses.
After reduction of exess iodine with ascorbic acid the mixture
was centrifuged. The supernatant was further purified by
Dowex H+ chromatography (9) and subsequently filtered (Ami-
con YM 10, 4000 g, 30 min, + 4°C). The HPLC-procedure
was performed as described by Goldberg et al. (8). The ratio of
neopterin determined after oxidation to native neopterin deter-
mined by non-oxidative analysis is 1 :0.46 (urine) and 1 :0.42
(serum).
Creatinine concentrations in urine were determined with the kit
(No. 124192) of Boehringer (Mannheim, Germany). All pterins
were from Dr. B. Schircks (Jona, Switzerland).
Results
The results of urine analyses of all melanoma patients
compared with the normal range (mean ± 2 standard
deviations) are shown in fig. 1. The majority of pa-
tients (85 of 101) presented urinary neopterin concen-
trations below the upper normal limit (mean
H- 2 S. D. of healthy controls). Urinary neopterin ex-
cretion of the only patient in this study with verified
metastatic disease (*M in fig. 1) at the time of analyses
was greatly elevated (1608 μιηοΐ/mol creatinine). Re-
sults for the two patients with a latency of diagnosed
metastases (m in fig. 1) and for one patient with
orbital infiltration (s) rank near the upper normal
limit. Neopterin was elevated in the serum of 7 of 43
melanoma patients (16%). The result for the above-
mentioned patient with metastatic disease at the time
of analysis was distinctly (!-» in fig. 2) elevated by a
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Fig. 1. Neopterin excretion by 101 patients with a choroidal
melanoma. M = Patient with verified metastatic disease
at the time of analyses, m = results of patients with
later diagnoses of metastases (7 and 10 months later),
S = melanoma patient with transscleral infiltration of
the orbit. Results of patients with an index (M, m, S)
are represented by an asterisk (*). Differences between
tumour patients and healthy controls were not signifi-
cant according to the result of Student's t-test (p > 0.8).
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Fig. 2. Neopterin in serum of 43 patients with a choroidal
melanoma, in relation to the range of healthy normals.
"1—»" indicates the result of an untreated melanoma
patient with metastatic disease, "2—»" of an untreated
melanoma patient with diagnosed metastatic disease 7
months after neopterin analyses. Differences between
normals and tumour patients were not significant (Stu-
dent's t-test, ρ > 0.9).
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Tab. 2. Neopterin in urine and serum of patients with choroidal
melanoma compared with results of a healthy control
group.
Tab. 3. Relative incidence of neopterin results of patients with
choroidal melanoma exceeding the upper limit of
healthy normals (mean + 2 S. D.).
Untreated, t um our patients
(n)
Partial tumour regression
(n)
Complete tumour regression
(n)
Healthy controls
(n)
Urine
( /mol
creatinine)
375 + 172
(17)
423 + 256
(33)
394 ± 179
(47)
410 + 101
(92)
Serum
(nmol/1)
8.7 ±
(8)
8.7 ±
(19)
9.7 ±
(14)
9.1 ±
(40)
1.5
3.5
3.0
1.6
Patients with present or later metastatic disease and orbital
infiltration ("M", "m", "S" and "—>" of figure 1 and 2) are not
included in this table (n = 4 for urine, n = 2 for serum). The
absolute number and percentages of melanoma patients ex-
ceeding the upper limit of healthy controls (mean ± 2 S. D.)
are listed in table 3.
factor of 9, compared with the mean of the control
group. The second array (2—> in fig. 2) indicates the
results for a patient diagnosed as having metastases
(liver) 7 months after pterin analyses.
The results of neopterin measurements in urine and
serum grouped according to the actual tumour state
are shown in table 2. Significant differences were not
found in the ANOVA (F-test) at a level of p < 0.1.
The relative incidence of patients exceeding the upper
limit (x + 2 S. D.) was rather consistent in all classi-
fied groups of patients, as seen in table 3.
Discussion
In summary, neopterin excretion in urine and the
serum concentrations of neopterin in patients with
malignant choroidal melanoma was elevated beyond
the upper limit only in a minor percentage (16%) of
all examined subjects. This result resembles the re-
ported magnitude of significantly increased neopterin
levels in other types of solid malignant tumours, for
example, early stage (I —III) breast cancer (10), and
head and neck cancer (11, 12). The relative incidence
of neopterin elevation beyond the upper limit infers
that neopterin concentrations are unsuitable as a tool
Untreated tumour patients
Partial tumour regression
Complete tumour regression
All patients
Urine
n
4/ 20
S/ 34
7/ 47
16/101
%
20
15
15
16
Serum
n
2/10
3/19
2/14
7/43
%
20.0
16
14
16
for the differentiation of choroidal melanomas from
non-neoplastic or other malignant tumours with
nearly identical clinical appearance.
The low percentage of indicative neopterin concen-
trations in patients with choroidal melanoma may
have two explanations, related to the possible im-
munological reactivity of the tumour. First, the av-
erage size of choroidal melanomas at the time of
diagnosis is small compared with many other malig-
nant tumours, since patients notice subjective symp-
toms at an early stage of the disease. This may explain
why immunological reactions are below a level de-
tectable by neopterin measurement. Second, the tum-
our-associated immunological reaction of choroidal
melanomas is not yet well established, and the avail-
able data indicates subnormal immunreactivity, at
least in a subgroup of melanoma patients (13, 14).
Although the small number of critical events in this
series of observation limits the possibility of a prog-
nostic calculation of neopterin results in these pa-
tients, it seems that neopterin is informative with
respect to metastatic spread of choroidal melanomas.
On the basis of the presented results, serum analysis
tends to be more discriminative than urine analysis.
The observation of elevated neopterin concentration
in the serum of a patient with a delayed diagnosis of
metastatic spread seems to indicate that neopterin is
at least a modest prognostic factor for the follow up
of these patients. This will be analysed further.
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